News|Articles|September 30, 2023
Neuro News Roundup: LGMD Awareness Day – Expert Insight and Latest Literature
Author(s)Isabella Ciccone, MPH
In honor of Limb-Girdle Muscular Dystrophy Awareness Day, held September 30, 2023, get caught up on some of the latest news in LGMD, with data updates and expert insights all in one place from the NeurologyLive® team.
Advertisement
The NeurologyLive® team has been hard at work in the year conducting interviews with thought leaders and covering the news on the latest updates in the clinical care of individuals with neuromuscular disorders such as limb-girdle muscular dystrophy (LGMD), and others.
For Limb-Girdle Muscular Dystrophy Awareness Day — September 30, 2023 —our team offers an update on those new developments in the literature and insight into the expert opinions about how they’re shaping the ever-changing care paradigm in LGMD into one place.
Click here for more coverage of the latest neuromuscular news from NeurologyLive®.
EXPERT INSIGHTS
LATEST LITERATURE
Dosing Commenced in Phase 3 FORTIFY of Limb-Girdle Muscular Dystrophy Type 2i
In recent news, BridgeBio Pharma announced its first patient dosed in its phase 3 FORTIFY clinical trial (NCT05775848) of BBP-418, an investigational oral substrate supplementation therapy in development for LGMD type 2I/R9 (LGMD2I/R9).1 As of now, the company has initiated over half of the planned clinical sites in the United States and is currently in the process of opening more sites in Europe and Australia to support global registration.
The company also recently met with the FDA to discuss the use of glycosylated α-dystroglycan levels, which are central to LGMD2I/R9 disease, as a surrogate end point in FORTIFY. Following the meeting, BridgeBio Pharma believes that there is potential for an accelerated approval pathway for BBP-418, with findings from the ongoing open-label phase 2 study (NCT04800874) as supportive data. Findings from the study thus far have suggested that the treatment may be well-tolerated and have a positive impact on key end points.2
FORTIFY is a randomized, double-blind, placebo-controlled study aimed at investigating the safety and efficacy of BBP-418. The trial has a planned interim analysis at 12 months with the potential of the results to support an accelerated approval. Patients will be assessed on the North Star Assessment for Dysferlinopathy (NSAD) and several other secondary end points, with findings expected to be announced in late 2024/early 2025 as confirmatory clinical data.
Patient Dosing Commenced in Phase 1/2 Gene Therapy Trial of Limb-Girdle Muscular Dystrophy Type 2I/R9
According to a recent announcement, the first patient has been dosed in the phase 1/2 LION-CS101 clinical trial (NCT05230459) assessing AskBio’s investigational gene therapy AB-1003 for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Recruitment for the trial remains ongoing.3
LGMD2I/R9, caused by mutations in the FKRP gene, is a form of LGMD that is characterized by weakness and wasting of the muscles in the arms and legs. AB-1003, also known as LION-101, uses an engineered viral vector—an adeno-associated virus (AAV)—to deliver a non-mutated version of the FKRP gene, by a single intravenous infusion. LGMD2I/R9 is a rare disease, estimated to affect more than 5000 people in the US and EU.
The phase 1/2 trial, double-blind, placebo-controlled, and dose-escalation in design, is expected to include 14 adults with genetically confirmed LGMD2I who are followed for a 52-week treatment period. Initiated midway through 2023, the trial’s main goal is safety, assessed through treatment-emergent adverse events (TEAEs), serious AEs, and dose limiting toxicity. Participants will be treated in sequential, dose-level cohorts with 2 arms of different doses and 1 placebo arm.
Efficacy and Tolerability on Display by SRP-9003 Over 2 Years in LGMD2E
Findings from a phase 1/2 study of the AAV-based gene therapy SRP-9003 suggest that treatment with the Sarepta Therapeutics agent resulted in sustained protein expression in muscle tissue and stabilized North Star Assessment for Dysferlinopathies (NSAD) scores at 2 years in patients with limb-girdle muscular dystrophy Type 2E (LGMD2E). The study enrolled children between the ages of 4 and 15 years with significant symptoms.4
The updated data were presented at the MDA 2021 Clinical and Scientific Conference, March 15-18, by Louise Rodino-Klapac, PhD, executive vice president and chief scientific officer, Sarepta Therapeutics. The study included 2 cohorts, both with a different dose of the gene therapy. Cohort 1 (n = 3) included patients who received 1.85 × 1013 vg/kg as a single intravenous infusion, and cohort 2 (n = 3) included those who received it at a dose of 7.41×1013 vg/kg—a dose selected based on findings from cohort 1.
All told, SRP-9003 elicited improvements for functional measures in all patients in the phase 1/2 study, including scores in time-to-rise, four-stair climb, 100-meter walk, and 10-meter walk tests. These were most pronounced in the high-dose group. In the low-dose cohort of the therapy with 2 years of follow-up, with data showing that mean beta-sarcoglycan (beta-SG) expression was increased by 54% in a western blot among treated patients—up from 36% at day 60. Similarly, in the high-dose cohort, the beat-SG expression was 62% at day 60, though long-term follow-up data were unavailable.
REFERENCES
1. BridgeBio pharma announces opportunity for accelerated approval pathway in limb-girdle muscular dystrophy type 2i (lgmd2i/r9) based on glycosylated alpha-dystroglycan (⍺dg) levels and announces first patient dosed in fortify phase 3 study. News Release. BridgeBio Pharma. Published July 31, 2023. Accessed September 28, 2023. https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-opportunity-accelerated-approval
2.BridgeBio announces positive phase 2 data for Limb-girdle muscular dystrophy type 2i (LGMD2i). News release. BridgeBio Pharma. March 14, 2022. Accessed September 28, 2023. https://www.globenewswire.com/en/news-release/2022/03/14/2402463/0/en/BridgeBio-Pharma-Announces-Positive-Phase-2-Data-for-Limb-girdle-Muscular-Dystrophy-Type-2i-LGMD2i
3. AskBio announces first patient dosed in phase 1/phase 2 trial of AB-1003 gene therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). News release. AskBio. August 3, 2023. Accessed September 28, 2023. https://www.prnewswire.com/news-releases/askbio-announces-first-patient-dosed-in-phase-1--phase-2-trial-of-ab-1003-gene-therapy-for-limb-girdle-muscular-dystrophy-type-2ir9-lgmd2ir9
4. Rodino-Klapac L. Safety, β-sarcoglycan Expression, and Functional Outcomes from Systemic Gene Transfer of rAAVrh74.MHCK7.SGCB in Limb-Girdle Muscular Dystrophy Type 2E. Presented at MDA Clinical and Scientific Conference 2021; March 15-18.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
NeurologyLive® Brain Games: September 14, 2025September 14th 2025
NeurologyLive® Friday 5 — September 12, 2025September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
3
NeurologyLive® Brain Games: September 14, 2025
4
